BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2399526)

  • 1. Adenosine potentiates the inhibitory effects of calcium channel antagonists on human platelet aggregation induced by thromboxane A2 or U46619.
    Johnson GJ; Leis LA; Francis GS
    Thromb Res; 1990 Jul; 59(1):139-48. PubMed ID: 2399526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets.
    Johnson GJ; Leis LA; Francis GS
    Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors.
    Onoda JM; Sloane BF; Honn KV
    Thromb Res; 1984 Jun; 34(5):367-78. PubMed ID: 6377570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor.
    Johnson GJ; Dunlop PC; Leis LA; From AH
    Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of verapamil and diltiazem on aggregatory responses in cat and rabbit platelet rich plasma.
    Lippton HL; Horwitz PM; McNamara DB; Landry AZ; Kadowitz PJ
    Prostaglandins Leukot Med; 1984 Oct; 16(1):121-30. PubMed ID: 6440150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil.
    Rostagno C; Abbate R; Gensini GF; Coppo M; Prisco D; Boddi M; Neri Serneri GG
    Thromb Res; 1991 Aug; 63(4):457-62. PubMed ID: 1754998
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of calcium channel blockers on platelet aggregation and thromboxane A2 formation: an in vivo double blind randomized study.
    Rostagno C; Prisco D; Paniccia R; Costanzo G; Poggesi L; Boddi M; Abbate R
    Thromb Res; 1990 Aug; 59(3):531-9. PubMed ID: 2237825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of prostaglandins, cAMP, and changes in cytosolic calcium on platelet aggregation induced by a thromboxane A2 mimic (U46619).
    Yun JC; Ohman KP; Gill JR; Keiser H
    Can J Physiol Pharmacol; 1991 May; 69(5):599-604. PubMed ID: 1650650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists.
    Bush LR; Smith SG
    Thromb Res; 1986 Nov; 44(3):377-89. PubMed ID: 2948294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation.
    Glusa E; Bevan J; Heptinstall S
    Thromb Res; 1989 Jul; 55(2):239-245. PubMed ID: 2528843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual effects of nimesulide, a COX-2 inhibitor, in human platelets.
    Saeed SA; Afzal MN; Shah BH
    Life Sci; 1998; 63(20):1835-41. PubMed ID: 9820127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of endothelial cells and calcium channel blockers on platelet aggregation.
    Yamada Y; Furui H; Furumichi T; Suzuki T; Yamauchi K; Yokota M; Hayashi H; Saito H
    Jpn Heart J; 1990 Mar; 31(2):201-15. PubMed ID: 2113109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human platelet aggregation and cytoplasmic calcium response by calcium antagonists: studies with aequorin and quin2.
    Ware JA; Johnson PC; Smith M; Salzman EW
    Circ Res; 1986 Jul; 59(1):39-42. PubMed ID: 3089642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin alpha IIb beta 3 and tumor-cell-induced platelet aggregation.
    Timar J; Chopra H; Rong X; Hatfield JS; Fligiel SE; Onoda JM; Taylor JD; Honn KV
    J Cancer Res Clin Oncol; 1992; 118(6):425-34. PubMed ID: 1377695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the inhibition of U46619-mediated human platelet activation by the trimetoquinol isomers. Evidence for endoperoxide/thromboxane A2 receptor blockade.
    Ahn CH; Romstedt KJ; Wallace LJ; Miller DD; Feller DR
    Biochem Pharmacol; 1988 Aug; 37(15):3023-33. PubMed ID: 3134894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of some calcium antagonists on aggregation by adrenalin and serotonin and on alpha-adrenoceptor radioligand binding in human platelets.
    Vinge E; Andersson TL; Larsson B
    Acta Physiol Scand; 1988 Jul; 133(3):407-16. PubMed ID: 2906509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of verapamil and nifedipine in thrombosis models.
    Myers AK; Forman G; Torres Duarte AP; Penhos J; Ramwell P
    Proc Soc Exp Biol Med; 1986 Oct; 183(1):86-91. PubMed ID: 3092231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of nifedipine, verapamil and diltiazem on pulmonary vascular resistance and vasoconstrictors in cats.
    Erdemli O; Hao Q; Cai B; Lippton HL; Hyman A
    Arch Int Pharmacodyn Ther; 1994; 328(2):165-79. PubMed ID: 7535994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers.
    Moore JB; Fuller BL; Falotico R; Tolman EL
    Thromb Res; 1985 Nov; 40(3):401-11. PubMed ID: 2417362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.